Cytodyn Inc (CYDY)

[stockorus]

I heard that VERU cc from link that was posted here yesterday. The CEO says they are checking their endpoints for 60 days instead of the usual 28. After 28, their placebo had 35% mortality which he said was the same as the Lancelet study for Tocilizumab. And he argued mortality is expected to increase for 60 days. Main point is that the "FDA agreed" to no additional data needed for efficacy etc. I don't see how given the way he said things they are not going to get the EUA. Can see it in the market reaction today as well.

Of course, we still have a chance to prove Leronlimab's worth in the Brazil trials. I thought that will be significant for us, just to prove the drug's efficacy in a certain condition that is more generally applicable than just for covid. But the trials are still suspended a month after DSMC approved the restart and Cytodyn said to have asked for ANVISA's permission. It is quite possible, given the financial situation and the waning of the pandemic, that the company is shifting to the other indications.